JOHN A. SCARLETT, M.D. - Corporate Board Profile

GERON CORP

Filing Date	Source Excerpt
2012-04-03	John A. Scarlett, M.D., has served as our Chief Executive Officer and a director since September 2011 and President since January 2012... As the only management representative on the Board... The 2011 Summary Compensation Table shows total compensation of $1,319,722.
2013-04-05	Dr. Scarlett does not receive any compensation for his Board service. ... John A. Scarlett, M.D., has served as our Chief Executive Officer and a director since September 2011 and President since January 2012. ... As the only management representative on the Board, Dr. Scarlett brings an insider's perspective in board discussions about Geron's business and strategic direction. ... Dr. Scarlett does not receive any compensation for his Board service.
2014-04-04	John A. Scarlett, M.D., has served as our Chief Executive Officer and a director since September 2011 and President since January 2012. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine. As the only management representative on the Board, Dr. Scarlett brings management's perspective to board discussions about Geron's business and strategic direction. In addition, the Board believes Dr. Scarlett's medical background and extensive drug development experience which provides substantial understanding of our clinical product opportunities, qualifies Dr. Scarlett to serve as a director.
2015-04-03	John A. Scarlett, M.D., has served as our Chief Executive Officer and a director since September 2011 and President since January 2012.
2016-04-01	John A. Scarlett, M.D., has served as our Chief Executive Officer and a director since joining Geron in September 2011 and President since January 2012. ... Dr. Scarlett does not receive any compensation for his Board service.
2017-03-24	John A. Scarlett, M.D. 66 No 2 President and Chief Executive Officer ... Director Compensation Table ... Scarlett does not receive any compensation for his Board service ... Summary Compensation Table ... John A. Scarlett, M.D. 2016 Salary $622,200 Option Awards $0 Non-Equity Incentive Plan Compensation $1,086,960 All Other Compensation $78,382 Total $2,160,842
2018-03-30	John A. Scarlett, M.D. 66 No 2 President and Chief Executive Officer
2019-04-22	John A. Scarlett, M.D. 68 No 2 Chairman of the Board, President, and Chief Executive Officer Dr. Scarlett has served as our Chairman of the Board effective December 2018, our Chief Executive Officer and a director since joining Geron in September 2011 and President since January 2012.
2020-04-14	Dr. Scarlett has served as our Chairman of the Board since December 2018, our Chief Executive Officer and a director since joining Geron in September 2011, and President since January 2012. Dr. Scarlett also serves as a member of the boards of directors for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, since February 2015, and CytomX Therapeutics, Inc., an oncology-oriented company, since June 2016. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held, oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation, a privately-held company focused on endocrine disorders. In 1995, he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S, a global pharmaceutical company. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. As the only management representative on the Board, Dr. Scarlett brings management’s perspective to the Board’s discussions about Geron’s business and strategic direction. In addition, the Board believes Dr. Scarlett’s deep understanding of what makes businesses work effectively and efficiently, as well as his medical background and extensive drug development experience, provide valuable insights to the Board. See discussion below regarding Board Leadership and Governance in connection with the appointment of a Lead Independent Director who provides leadership for the independent members of the Board. Serving as a director for other publicly-held biopharmaceutical companies provides Dr. Scarlett with alternate viewpoints on business strategy and board decision-making, which we believe enhances his contributions to our Board. Dr. Scarlett has demonstrated his ability to dedicate sufficient time and focus on his duties as a member of our Board and attended 100% of our Board meetings in 2019. In accordance with our Board’s standard practice, Dr. Scarlett reviews scheduled Board meeting dates a year in advance to confirm availability to participate and attend all our Board meetings, and prioritizes Geron’s meetings over Chiasma and CytomX board meetings. Accordingly, the Board believes Dr. Scarlet’s business and medical expertise acquired in successfully holding executive and leadership positions in biotechnology companies, and his demonstrated reliability and commitment to service on our Board, qualifies him to serve as a director and Chairman of the Board.
2021-03-22	John A. Scarlett, M.D. 70 No 2 Chairman of the Board, President, and Chief Executive Officer
2022-03-22	John A. Scarlett, M.D. 71 No 1 Chairman of the Board, President and Chief Executive Officer
2023-04-12	John A. Scarlett, M.D. 72 No Chairman of the Board, President and Chief Executive Officer Compensation: None for Board service
2024-03-27	John A. Scarlett, M.D. has served as our Chief Executive Officer and a director since September 2011 and President since January 2012 and was appointed as Chairman of the Board in December 2018. Dr. Scarlett does not receive separate compensation for serving as a member of our Board. For the year ended December 31, 2023, Dr. Scarlett’s total compensation was $4,924,092, including salary, bonus, option awards, non-equity incentive plan compensation, and other compensation.